A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs RG 4733 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 23 Dec 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 03 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2015 Planned End Date changed from 1 Sep 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.